The MHRA has granted marketing authorisation for diroximel fumarate as oral treatment for relapsing-remitting multiple sclerosis.
An AI-based diagnostic tool is being developed through a biotech startup.
We use cookies only to remember your preferences and provide better browsing experience. We do not sell user information. Here is our privacy policy.